Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

Are generalist investors good or bad for biotech? How did Elaine and Adam’s trip to New York go? And how long has George Church owned that brown corduroy blazer?

We cover all that and more on the latest episode of “The Readout Loud.” Mizuho analyst Jared Holz joins us to discuss what the Federal Reserve’s long-awaited decision to lower interest rates means for biotech stocks and startups. Elaine, Adam, and Allison also discuss the latest news in life sciences, including the use of cannabinoid receptor drugs in weight loss and the Lasker Awards, a.k.a. “America’s Nobel.”

For more on Novo Nordisk and Corbus Pharmaceuticals’ CB1 work, go here; for more on the Lasker Award recipients, click here; for more on Applied Therapeutics’ cancelled Food and Drug Administration meeting, click here; and to learn more about George Church’s new startup, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

Social relationships buffer the effects of negative childhood experiences on frailty

Frailty is a serious concern in later-life adults due to its association with additional health risks including disability, falls, hospitalization and mortality.

September 22, 2023

Opinion | The Ebb and Flow of Mentorship in Medicine

Lazarus is an adjunct professor of psychiatry. Reconnecting with former mentors can be both a nostalgic and enlightening experience, often offering insights into how our

October 2, 2024

Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

Treatment with the antibody drug-conjugate ifinatamab deruxtecan (I-DXd) showed promising activity in pretreated patients with extensive-stage small cell lung cancer (SCLC), particularly those treated at

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.